{Reference Type}: Journal Article
{Title}: Value of the tumor inhibitor of cellular immunity PDL-1 in the incidence of venous thrombosis in patients with gastric cancer.
{Author}: Lorente M;Doello K;
{Journal}: Med Clin (Barc)
{Volume}: 162
{Issue}: 9
{Year}: 2024 05 17
{Factor}: 3.2
{DOI}: 10.1016/j.medcli.2024.01.003
{Abstract}: Gastric cancer is one of the cancers most associated with thromboembolic phenomena. The objective of this article is to study if there is a correlation between thromboembolic phenomena in gastric cancer and tumor expression of PDL-1.<BR>To this end, the association between thromboembolic events and PDL-1 expression was retrospectively studied in a sample of 46 patients from our hospital.<BR>The results obtained revealed a statistically significant difference between the percentage of thromboembolic events between positive and negative PDL-1 with an increase in the latter with a P value of 0.034.<BR>In conclusion, the expression of PDL-1, and with it, of an inhibitory factor of the cellular immune response, correlates with a decrease in thromboembolic events in patients with gastric cancer, which could indicate the crucial role of the immune response in which thromboembolic events occur.